The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.
Yosuke Kawashima
No relevant relationships to disclose
Akira Inoue
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Kunihiko Kobayashi
No relevant relationships to disclose
Toshiyuki Kozuki
No relevant relationships to disclose
Shoichi Kuyama
No relevant relationships to disclose
Tomohiro Sakakibara
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Hajime Asahina
No relevant relationships to disclose
Akiko Hisamoto
No relevant relationships to disclose
Taku Nakagawa
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose